Treatment with the PPARγ agonist rosiglitazone prevents and reverses established hypoxia-induced pulmonary hypertension (HPH) by suppressing superoxide production and platelet-derived growth factor receptor-β signaling, and by increasing expression of the phosphatase and tensin homolog (PTEN) (Nisbet et al., 2010). Here, PPARG is linked to pulmonary hypertension.